Perspective · 31 Mar 2023
CommentaryPublished 30 Jun 2025
Surface-Functionalized Nanocarriers: Advancing Targeted Drug Delivery
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction Surface-functionalized nanocarriers are engineered nanoparticles whose surfaces are modified with specific chemical groups, ligands, or biomolecules to enhance their therapeutic performance. These modifications allow nanocarriers to interact selectively with target cells or tissues, improve circulation time, evade immune clearance, and achieve controlled drug release. In modern medicine, surface-functionalized nanocarriers are increasingly used in oncology, infectious disease therapy, gene delivery, and diagnostics. By combining nanotechnology with targeted functionalization, these systems enable precise, efficient, and safe drug delivery, overcoming the limitations of conventional formulations [1]. Discussion The primary advantage of surface-functionalized nanocarriers lies in their ability to achieve targeted delivery. Functionalization involves attaching ligands such as antibodies, peptides, aptamers, carbohydrates, or small molecules to the nanoparticle surface. These ligands specifically bind to receptors expressed on diseased cells or tissues, enabling selective accumulation at the target site [2]. For instance, in cancer therapy, nanoparticles functionalized with folate ligands or anti-HER2 antibodies preferentially bind to tumor cells expressing these receptors, improving drug concentration at the tumor and reducing systemic toxicity [3]. Stealth and circulation enhancement is another important feature. Surface modifications with hydrophilic polymers such as polyethylene glycol (PEG) prevent opsonization and clearance by the reticuloendothelial system (RES). This “stealth” property prolongs the circulation time of nanocarriers, increasing the likelihood of reaching the target tissue. Additionally, pH-sensitive or enzyme-responsive surface coatings can facilitate controlled and stimuli-responsive drug release in pathological environments such as acidic tumor tissues or enzyme-rich infection sites [4]. Surface-functionalized nanocarriers are highly versatile in terms of payload delivery. They can carry chemotherapeutic drugs, nucleic acids, proteins, or imaging agents, enabling therapeutic and diagnostic applications—so-called theranostics. For example, magnetic nanoparticles functionalized with targeting ligands and loaded with chemotherapeutic drugs allow simultaneous tumor imaging and therapy. Similarly, nanoparticles conjugated with siRNA or mRNA can deliver genetic material to specific cells, enabling gene therapy applications [5]. The clinical applications of surface-functionalized nanocarriers are diverse. In oncology, they improve the efficacy of chemotherapy, reduce side effects, and overcome multidrug resistance. In infectious diseases, targeted nanocarriers deliver antibiotics or antiviral agents directly to infected tissues, enhancing treatment outcomes and reducing resistance. In regenerative medicine, nanoparticles functionalized with growth factors or signaling molecules promote tissue repair and healing at specific sites. Despite their promise, challenges remain. Optimizing ligand density, maintaining nanoparticle stability, ensuring biocompatibility, and avoiding immune responses are critical for successful application. Large-scale manufacturing, reproducibility, and regulatory approval also require careful attention. Continued research in material science, nanotechnology, and molecular biology is essential to overcome these hurdles. Conclusion Surface-functionalized nanocarriers represent a cutting-edge approach in targeted drug delivery, combining specificity, controlled release, and enhanced circulation to improve therapeutic efficacy. By attaching ligands or functional groups to nanoparticle surfaces, these systems achieve precise targeting, minimize off-target effects, and enable multifunctional applications such as theranostics and gene delivery. While challenges in biocompatibility, scalability, and regulatory approval remain, advances in nanotechnology and molecular engineering continue to expand their potential [6]. References Nybo H, Petersen HC, Gaist D, Jeune B, Andersen K, et al. (2003) Predictors of mortality in 2,249 nonagenarians—the Danish 1905-Cohort Survey. J Am Geriatr Soc 51: 1365–1373. Indexed at, Google Scholar, Crossref Von Strauss E, Fratiglioni L, Viitanen M, Forsell Y, Winblad B (2000) Morbidity and comorbidity in relation to functional status: a community-based study of the oldest old (90+ years). J Am Geriatr Soc 48: 1462–1469. Indexed at, Google Scholar, Crossref Andersen HR, Jeune B, Nybo H, Nielsen JB, Andersen-Ranberg K, et al. (1998) Low activity of superoxide dismutase and high activity of glutathione reductase in erythrocytes from centenarians. Age Ageing 27: 643–648. Indexed at, Google Scholar, Crossref Ankri J, Poupard M (2003) Prevalence and incidence of dementia among the very old. Review of the literature. Rev Epidemiol Sante Publique 51: 349–360. Indexed at, Google Scholar Wilkinson TJ, Sainsbury R (1998) The association between mortality, morbidity and age in New Zealand’s oldest old. Int J Aging Hum Dev 46: 333–343. Indexed at, Google Scholar, Crossref
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Opinion · 3 Nov 2022
Nanocarriers and their Characterization in Targeted Drug Delivery Systems
Editorial · 29 Dec 2025
pH-Sensitive Drug Delivery: Targeted Therapy Through Smart Nanocarriers
Conference abstract · 7 Mar 2016
Physical fields may promote nanocarriers effectiveness in targeted drug delivery
Conference abstract · 17 Aug 2015
Novel tumor-targeted zein-based nanocarriers for co-delivery of anti-cancer drugs in breast cancer therapy
More from this journal
The newest in Research & Reviews: Journal of Pharmaceutics and Nanotechnology.
Editorial · 29 Dec 2025
Scale-Up and Manufacturing of Nanomedicines: From Laboratory Innovation to Commercial Production
Editorial · 29 Dec 2025
Nanotoxicity Assessment: Evaluating the Safety of Nanomaterials in Biomedical Applications
Editorial · 29 Dec 2025
Sustained and Controlled Release Formulations: Enhancing Therapeutic Efficacy and Patient Compliance
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalResearch & Reviews: Journal of Pharmaceutics and Nanotechnology
- SubjectPharmaceutical Sciences
- SubjectNanotechnology
- BylineArticles whose byline prints “Emma Roy”
